Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Tax Provision: ¥7.5 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603229 Zhejiang Ausun Pharmaceutical Co Ltd SHSE:603229
81 GF Score
Price ¥7.79
GF Value ¥9.40
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Zhejiang Ausun Pharmaceutical Co Tax Provision?

Zhejiang Ausun Pharmaceutical Co SHSE:603229 -1.39% 81 Tax Provision is ¥7.5 Mil as of Jun. 2026. GuruFocus rates SHSE:603229 with a GF Score™ of 81/100 and a GF Value™ of ¥9.40 (Modestly Undervalued). The stock has 10 warning signs investors should review.

Zhejiang Ausun Pharmaceutical Co's tax provision for the three months ended in Jun. 2026 was ¥0.2 Mil. Its tax provision for the trailing twelve months (TTM) ended in Jun. 2026 was ¥7.5 Mil.

Zhejiang Ausun Pharmaceutical Co Tax Provision Historical Data

* Premium members only.

The historical data trend for Zhejiang Ausun Pharmaceutical Co's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Ausun Pharmaceutical Co Tax Provision Chart

Zhejiang Ausun Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.46 -20.48 -36.86 -33.41 -7.33

Zhejiang Ausun Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.80 -0.98 18.98 -10.67 0.21
SHSE:603229
81GF Score
Zhejiang Ausun Pharmaceutical Co Ltd SHSE:603229
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Ausun Pharmaceutical Co Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥7.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of ¥7.5 Mil mean?
Zhejiang Ausun Pharmaceutical Co (SHSE:603229) has a Tax Provision of ¥7.5 Mil as of Jun. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Zhejiang Ausun Pharmaceutical Co and its competitors.
Is Zhejiang Ausun Pharmaceutical Co's Tax Provision too high?
Zhejiang Ausun Pharmaceutical Co's current Tax Provision is ¥7.5 Mil. Overall, Zhejiang Ausun Pharmaceutical Co has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Ausun Pharmaceutical Co's Tax Provision compare to VRTX and REGN?
Zhejiang Ausun Pharmaceutical Co's Tax Provision of ¥7.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Zhejiang Ausun Pharmaceutical Co and its competitors. Zhejiang Ausun Pharmaceutical Co's current Tax Provision is ¥7.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Ausun Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co (SHSE:603229) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥9.40, compared to a current price of ¥7.79 — trading 17.1% below its estimated fair value. The current Tax Provision is ¥7.5 Mil. Zhejiang Ausun Pharmaceutical Co's overall GF Score™ is 81/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Zhejiang Ausun Pharmaceutical Co (SHSE:603229), the current Tax Provision is ¥7.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥7.79 is trading 17.1% below its estimated GF Value™ of ¥9.40. GuruFocus considers Zhejiang Ausun Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:603229:

  • Tax Provision: ¥7.5 Mil
  • GF Value™: ¥9.40 vs. price of ¥7.79 (17.1% below fair value)
  • GF Score™: 81/100 with 10 warning signs

No single metric tells the full story. See the SHSE:603229 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Ausun Pharmaceutical Co Business Description

Address No.5, Donghai 4th Avenue, chemical raw materials base Linhai Park East, Zhejiang Province, Taizhou, CHN, 317016
Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.
81GF Score

Get the complete analysis for SHSE:603229

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥7.79
Price
¥9.40
GF Value